100 likes | 277 Views
Office for Life Sciences. Dr Robert Sullivan Director, Office for Life Sciences 22/04/2009. Office for. Life Sciences. Creation of the Office. Announced by the Prime Minister at the UK Pharma Summit on 27 th January. Led by Lord Drayson.
E N D
Office for Life Sciences Dr Robert Sullivan Director, Office for Life Sciences 22/04/2009 Office for Life Sciences
Creation of the Office Announced by the Prime Minister at the UK Pharma Summit on 27th January. Led by Lord Drayson. It’s purpose is ‘To drive short-term coordinated, coherent and visible action by Government and industry to ensure that the UK is the place of choice for life sciences companies to locate their business, retaining resources and skills.’
The Office is made up from loans from relevant departments UKTI DIUS INDUSTRY Pharmaceutical Medical Biotech Medical Devices Informatics OFFICE FOR LIFE SCIENCES BERR HMT DH DH
Cross Whitehall working The Office also works closely with Intellectual Property Office Research Councils Technology Strategy Board Longer term the Office will produce a joint Government-Industry Strategy. The work of the Office for Life Sciences is part of the ‘New Industrial Activism’ policy.
Ways of Working Weekly meetings between industry, Lord Drayson and the Office. ‘Pillar working groups’ concentrating on main areas to drive forward focussed and rapid progress. An Advisory Group, including Lord Darzi and Sally Davies, will meet occasionally.
The work is focussed around 4 Pillars NHS AS AN INNOVATION CHAMPION BUILDING AN INTEGRATED INDUSTRY ACCESS TO FINANCE & INVESTMENT UNDERPINNING ISSUES • NICE as a catalyst for innovation • Faster uptake of medicines and technologies • Improving situation for clinical trials • Improve regulation • Encouraging spin-outs • Creating life sciences innovation clusters • Ensuring a sustainable skills base and pipeline • Creating the right funding environment • Examining potential of R&D tax credits and how to encourage development and exploitation of IP • Marketing the UK as a place to invest in life sciences • Improved industry characterisation metrics to be held on database
In Vitro Diagnostics Personalised medicine OLS working with pharmaceutical and diagnostics sectors Improved diagnostic tools will be needed e.g. Access to bio-banks Improved clinician knowledge of diagnostic methods needed for implementation Regulation
For more information… www.dius.gsi.gov.uk/ols will be updated regularly with information as it becomes available.